Tag:
Protalix
Latest Headlines
Latest Headlines
FDA OK for Gaucher drug opens new market for Pfizer, Protalix
After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).
Protalix shares dive on Gaucher's drug delay at FDA
Protalix BioTherapeutics ( $PLX ) reported this morning that the FDA is putting off its deadline for a final decision on its drug for Gaucher's disease. The new deadline is May 1, and the news quickly
Genzyme's shortage opens door to rival Protalix
Manufacturing remediation chugs along at Genzyme , which anticipates some supply constraints of Gaucher-disease treatment Cerezyme before the supply outlook improves in February. Operating under a
Protalix showcases PhIII data for rare-disease drug in Pfizer pact
Amid its latest run for FDA approval of its Gaucher disease drug tied into a collaboration with Pfizer ( $PFE ), Protalix BioTherapeutics ( $PLX ) has published details from its Phase III package that
FDA hands Protalix a CRL for Gaucher's disease drug
The FDA has issued a complete response letter for Protalix's Gaucher's disease drug taliglucerase alfa. But the good news for Protalix is that the developer won't be required to conduct any
Protalix boasts of "revolutionary" advance on oral Gaucher's drug
Israel's Protalix BioTherapeutics says it is blazing a scientific path that will lead to a new recombinant protein therapeutic for Gaucher's disease that can be delivered orally, eliminating the need
Brazil to join ranks of Gaucher's drug makers
In a shot across Genzyme's damaged bow, Protalix and Pfizer are aligning with Brazil in a licensing deal for taliglucerase alfa, a treatment for Gaucher's disease. The Brazilian health minister says
Will new Genzyme stumble cripple its bargaining position?
After taking a good hard look at its troubled Allston plant, Genzyme ( GENZ ) has extended the scope of its repair mission to up to four years--which could extend federal oversight until late in the
Protalix pits plants vs. mammals in sexy bet
Pfizer's bet on Protalix--and in taking on the temporarily manufacturing-challenged Genzyme in the Gaucher's disease market--is a new-tech risk-tolerance exercise. Positive Phase III results for
Genzyme rivals unleash barrage of promising Gaucher data
Both Shire Pharmaceuticals and Protalix have rolled out a fresh barrage of promising late-stage data for their next-gen Gaucher disease drugs, with each taking another big step toward a market that
